The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.

Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a ...

In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the University ...

(Reuters) - BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the ...

The university filed a lawsuit against BioNTech four months ago, claiming that the company licensed vaccine technology ...

In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the National Institutes of Health concerning royalties and other related amounts allegedly ...

BioNTech has come to a settlement with both NIH and the University of Pennsylvania, by which the German pharma firm had ...

BioNTech SE ( (BNTX) ) has provided an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top Wall Street ...

Concurrently, BioNTech (BNTX) announced a settlement agreement worth $467M with Penn to resolve a lawsuit filed by the university over royalty claims related to the COVID-19 shot. The deal ...

Upon partial receipt of the Settlement Payment, Penn has agreed to dismiss with prejudice the litigation Penn filed against the Company and its former subsidiary, BioNTech RNA Pharmaceuticals ...

Dec 27 (Reuters) - BioNTech (22UAy.DE), opens new tab has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennsylvania over the ...